NO20071326L - Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser - Google Patents

Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser

Info

Publication number
NO20071326L
NO20071326L NO20071326A NO20071326A NO20071326L NO 20071326 L NO20071326 L NO 20071326L NO 20071326 A NO20071326 A NO 20071326A NO 20071326 A NO20071326 A NO 20071326A NO 20071326 L NO20071326 L NO 20071326L
Authority
NO
Norway
Prior art keywords
treatment
psychotic disorders
tricyclic derivatives
condensed tricyclic
condensed
Prior art date
Application number
NO20071326A
Other languages
English (en)
Norwegian (no)
Inventor
Steven Mark Bromidge
Alessandra Pasquarello
Markus Bergauer
Matteo Biagetti
Colin Philip Leslie
Jonathan Bentley
Barbara Bertani
Manuela Borriello
Massimo Gianotti
Enrica Granci
Valeria Zucchelli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419315A external-priority patent/GB0419315D0/en
Priority claimed from GB0507386A external-priority patent/GB0507386D0/en
Priority claimed from GB0515010A external-priority patent/GB0515010D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20071326L publication Critical patent/NO20071326L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20071326A 2004-08-31 2007-03-12 Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser NO20071326L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0419315A GB0419315D0 (en) 2004-08-31 2004-08-31 Compounds
GB0507386A GB0507386D0 (en) 2005-04-12 2005-04-12 Compounds
GB0515010A GB0515010D0 (en) 2005-07-21 2005-07-21 Compounds
PCT/EP2005/009379 WO2006024517A1 (en) 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
NO20071326L true NO20071326L (no) 2007-05-03

Family

ID=35106764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071326A NO20071326L (no) 2004-08-31 2007-03-12 Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser

Country Status (17)

Country Link
US (1) US20120022056A1 (https=)
EP (1) EP1786822A1 (https=)
JP (1) JP2008511574A (https=)
KR (1) KR20070057885A (https=)
CN (1) CN101048414B (https=)
AR (1) AR053307A1 (https=)
AU (1) AU2005279278A1 (https=)
BR (1) BRPI0514377A (https=)
CA (1) CA2578781A1 (https=)
IL (1) IL181387A (https=)
MA (1) MA28871B1 (https=)
MX (1) MX2007002548A (https=)
NO (1) NO20071326L (https=)
NZ (1) NZ553506A (https=)
PE (1) PE20060653A1 (https=)
TW (1) TW200619221A (https=)
WO (1) WO2006024517A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
JP4324221B2 (ja) * 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Ｐｐａｒアゴニスト活性を有する誘導体
JP2009523820A (ja) * 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
JP2010504367A (ja) 2006-09-26 2010-02-12 グラクソ グループ リミテッド 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
GB0800840D0 (en) 2008-01-17 2008-02-27 Glaxo Group Ltd Novel salt
DK2268644T3 (da) 2008-03-05 2011-10-10 Boehringer Ingelheim Int Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP5947382B2 (ja) 2011-08-17 2016-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フロ［３，４−ｃ］キノリン誘導体、このような化合物を含む薬物、それらの使用及びそれらの調製方法
EP2792679A1 (en) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Tricyclic triazolic compounds
JP6523267B2 (ja) * 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20120022056A1 (en) 2012-01-26
EP1786822A1 (en) 2007-05-23
WO2006024517A1 (en) 2006-03-09
PE20060653A1 (es) 2006-09-27
IL181387A (en) 2011-10-31
KR20070057885A (ko) 2007-06-07
CN101048414A (zh) 2007-10-03
MA28871B1 (fr) 2007-09-03
AR053307A1 (es) 2007-05-02
AU2005279278A1 (en) 2006-03-09
TW200619221A (en) 2006-06-16
CA2578781A1 (en) 2006-03-09
NZ553506A (en) 2010-02-26
IL181387A0 (en) 2007-07-04
BRPI0514377A (pt) 2008-06-24
MX2007002548A (es) 2007-04-24
CN101048414B (zh) 2011-09-07
JP2008511574A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
NO20071326L (no) Kondenserte trisykliske derivater for behandling av psykotiske forstyrrelser
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
CY2018028I2 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1572215T3 (da) Benzo[D]azepin-derivater til behandling af neurologiske lidelser
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
NO20055588D0 (no) Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
PL1708991T3 (pl) Pochodne sulfonoamidu do leczenia chorób
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK1847524T3 (da) Terphenylderivater til behandling af Alzheimers sygdom
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DK1907374T3 (da) Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
FI20040180L (fi) Koostumus psoriasis-taudin hoitamiseksi
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
DK1940447T3 (da) Behandling af neurodegenrative lidelser
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen
IS8225A (is) 2-etoxý-3-fenýlprópíónsýruafleiður til að meðhöndla fitusjúkdóma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application